Edgar Filing: HealthWarehouse.com, Inc.

Unassociated Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011

¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 0-13117

HealthWarehouse.com, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		22-2413505
(State or Other Jurisdiction		(I.R.S. Employer
of Incorporation or Organization)		Identification No.)

7107 Industrial Road, Florence, KY		41042
(Address of Principal Executive Offices)		(Zip Code)

(513) 618-0911

(Registrant’s Telephone Number, Including Area Code)

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ¨		Accelerated Filer ¨

Non-accelerated Filer ¨		Smaller Reporting Company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of August 8, 2011, there were 11,082,926 shares of common stock outstanding.

HEALTHWAREHOUSE.COM, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2011

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements		1

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		12

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk		19

ITEM 4. Controls and Procedures		19

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings		21

ITEM 1A. Risk Factors		21

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds		21

ITEM 3. Defaults upon Senior Securities		21

ITEM 4. (Removed and Reserved)		21

ITEM 5. Other Information		21

ITEM 6. Exhibits		22

SIGNATURES		23

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2011			December 31, 2010
	(Unaudited)
Assets
Current assets
Cash	$	111,887		$	1,397,583
Accounts receivable, net of allowance for doubtful accounts of $150,000 and $120,000,respectively		713,678			604,524
Inventories – finished goods		678,846			374,519
Employee advances		57,571			51,429
Prepaid expenses and other current assets		148,240			126,708
Total current assets	$	1,710,222		$	2,554,763

Property and equipment, net		358,445			320,328
Website development costs, net of accumulated amortization of $189,575 and $139,475, respectively		10,821			60,921
Intangible assets, net of accumulated amortization of $41,270 and $0, respectively		652,065			-

Total assets	$	2,731,553		$	2,936,012

Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable – related parties	$	563,308		$	232,858
Accounts payable – trade		1,262,583			807,481
Accrued expenses and other current liabilities		221,549			240,098
Convertible notes, net of deferred debt discount of $0 and $9,658, respectively		-			215,342

Total current liabilities	$	2,047,440		$	1,495,779

Convertible notes payable, net of deferred debt discount of $440,621 and $600,354, respectively		559,379			399,646

Total liabilities	$	2,606,819		$	1,895,425

Commitments and contingencies

Stockholders’ equity
Convertible preferred stock - Series A – par value $.001 per share; authorized 1,000,000 shares; 200,000 shares designated Series A; no shares issued and outstanding (aggregate liquidation preference $0)		-			-
Convertible preferred stock - Series B – par value $.001 per share; authorized 1,000,000 shares; 625,000 shares designated Series B; 368,862 and 365,265 shares issued, and outstanding respectively (aggregate liquidation preference $3,485,746 and $3,451,754, respectively)		369			365
Common stock – par value $.001 per share; authorized 50,000,000 shares; 10,604,354 and 10,278,934 shares issued and outstanding		10,605			10,279
Additional paid-in capital		10,917,226			9,540,036
Accumulated deficit		(10,803,466	)		(8,510,093	)
Total stockholders’ equity		124,734			1,040,587
Total liabilities and stockholders’ equity	$	2,731,553		$	2,936,012

The accompanying notes are an integral part of these condensed consolidated financial statements.

HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended June 30, 2011			For the Three Months Ended June 30, 2010			For the Six Months Ended June 30, 2011			For the Six Months Ended June 30, 2010

Net sales	$	2,519,721		$	1,766,662		$	4,804,273		$	3,002,176

Cost of sales		1,404,192			1,282,831			2,702,335			1,890,246
Gross profit		1,115,529			483,831			2,101,938			1,111,930

Operating expenses:

Selling, general and administrative expenses		2,116,736			1,054,667			4,070,434			1,935,450

Loss from operations		(1,001,207	)		(570,836	)		(1,968,496	)		(823,520	)

Other income (expense):
Gain on litigation settlement		-			48,887			-			48,887
Interest income		1,635			17			2,797			79
Interest expense		(100,522	)		(127,397	)		(205,674	)		(193,680	)
Total other expense		(98,887	)		(78,493	)		(202,877	)		(144,714	)

Net loss	$	(1,100,094	)	$	(649,329	)	$	(2,171,373	)	$	(968,234	)

Series B Convertible Preferred Stock:
Contractual dividends		(61,000	)		-			(122,000	)		-

Loss attributable to common stockholders	$	(1,161,094	)	$	(649,329	)	$	(2,293,373	)	$	(968,234	)

Per share data:
Net loss per common share from operations - Basic and diluted	$	(0.10	)	$	(0.07	)	$	(0.21	)	$	(0.10	)
Series B convertible preferred stock contractual dividends		(0.01	)		-			(0.01	)		-
Net loss attributable to common stockholders per share – basic and diluted	$	(0.11	)	$	(0.07	)	$	(0.22	)	$	(0.10	)

Weighted average number of common shares outstanding - Basic and diluted		10,597,125			9,984,334			10,542,390			9,937,806

The accompanying notes are an integral part of these condensed consolidated financial statements.

HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Six Months Ended June 30, 2011			For the Six Months Ended June 30, 2010
Cash flows from operating activities
Net loss	$	(2,171,373	)	$	(968,234	)
Adjustments to reconcile net loss to net cash from operating activities:
Provision for doubtful accounts		30,000			18,358
Depreciation and amortization		126,127			95,057
Stock-based compensation		425,193			216,846
Amortization of deferred debt discount		169,391			144,381
Gain on extinguishment of debt		-			(48,887	)
Changes in operating assets and liabilities:
Accounts receivable		(139,154	)		(488,345	)
Inventories - finished goods		(104,327	)		(177,984	)
Prepaid expenses and other current assets		(21,532	)		37,731
Accounts payable – related parties		330,450			240,357
Accounts payable – trade		455,102			(49,299	)
Accrued expenses and other current liabilities		(106,557	)		46,615
Net cash used in operating activities		(1,006,680	)		(933,404	)

Cash flow from investing activities
Acquisition of Hocks.com assets		(200,000	)		-
Employee advance		(6,142	)		(51,429	)
Refund from the return of property and equipment		15,732			-
Acquisition of property and equipment		(88,606	)		(35,348	)
Net cash used in investing activities		(279,016	)		(86,977	)

Cash flows from financing activities
Proceeds from notes payable		-			500,000
Proceeds from sale of convertible notes		-			50,000
Advances from former director		-			422,000
Repayment of advances from former director		-			(143,000	)
Net cash provided by financing activities		-			829,000

Net decrease in cash		(1,285,696	)		(191,181	)

Cash - beginning of period		1,397,583			191,181

Cash - end of period	$	111,887		$	-

Cash paid for:
Interest	$	9,117		$	-
Taxes	$	-		$	-

Non-cash investing and financing activities:
Conversion of convertible notes to common stock	$	225,000		$	400,000
Exchange of common stock to acquire assets of Hocks.com	$	693,335		$	-
Issuance of series B preferred stock for settlement of accrued dividends	$	33,992		$	-
Accrual of series B preferred stock contractual dividend	$	122,000		$	-
Cashless exercise of warrants into common stock	$	14		$	-
Deferred debt discount – notes payable	$	-		$	304,037

Purchase price allocation:

Current assets - Inventory	$	200,000
Customer relationships		693,335
Net fair value of assets acquired/Total purchase price	$	893,335

The accompanying notes are an integral part of these condensed consolidated financial statements.

HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

1. Organization and Basis of Presentation

Healthwarehouse.com, Inc. (the “Company”) is a U.S. licensed virtual retail pharmacy (“VRP”) and healthcare e-commerce company that sells brand name and generic prescription drugs as well as over-the-counter (“OTC”) medical products. The Company’s objective is to be viewed by individual healthcare product consumers as a low-cost, reliable and hassle-free provider of prescription drugs and OTC medical products. The Company is presently licensed as a mail-order pharmacy for sales to 50 states and the District of Columbia.

The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for certain financial information and the instructions to Form 10-Q and Article 10 of the Regulation S-X. Accordingly, the condensed consolidated balance sheet as of June 30, 2011 and the condensed consolidated statements of operations for the three and six months ended June 30, 2011 and 2010 and cash flows for six months ended June 30, 2011 and 2010, have been prepared by the Company without being audited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to make the Company’s condensed consolidated financial position, results of operations and cash flows at June 30, 2011 not misleading have been made. The condensed consolidated results of operations for the three and six months ended June 30, 2011 are not necessarily indicative of results that would be expected for the full year or any other interim period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the current report on Form 10-K filed with the Securities and Exchange Commission on April 15, 2011.

2. Management’s Liquidity Plans

Since inception, the Company has financed its operations primarily through product sales to customers and debt and equity financing agreements. As of June 30, 2011, the Company had $111,887 in cash and a working capital deficiency of $337,218 which represents decreases of $1,285,696 and $1,396,202 from December 31, 2010, respectively. During the six months ended June 30, 2011, the Company generated revenue of $4,804,273 and a net loss of $2,171,373. For the six months ended June 30, 2011, cash flows included net cash used in operating activities of $1,006,680 and net cash used in investing activities of $279,016.

Management believes that the Company has taken certain steps to improve its operations and cash flows, including improved inventory management and an increase in the number of suppliers. The acquisition of Hocks.com (see note 11) is also expected to improve the operating productivity and efficiency of the Company’s expenditures for selling, general and administrative activities. Further the Company has taken additional steps to increase the profitability derived from the acquisition of Hocks.com including significantly increasing the gross margin while decreasing the amounts spent on rent and payroll related expenses. Management believes that this plan will be successful, but there can be no such assurance.

Subsequent to June 30, 2011, the Company raised approximately $1,500,000 from the sale of 428,572 shares of common stock. Considering its financial resources and current operating projections, the Company believes that its financial resources will be sufficient to fund its operation through at least the next twelve months. Management believes that if the Company needs to raise additional capital in order to meet operations and execute its business plan, it will be successful. However, there is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to extend payables and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

3. Summary of Significant Accounting Policies

Principles of Consolidation

The condensed consolidated financial statements include the accounts of HealthWarehouse.com, Inc., Hwareh.com, Inc., ION Holding NV, ION Belgium NV, and Hocks.com, Inc. its wholly-owned subsidiaries. All material inter-company balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s significant estimates include the allowance for doubtful accounts, depreciation, valuation of intangible assets, stock-based compensation, evaluation of warrants, debt discount and deferred tax assets, including a valuation allowance.

Reclassifications

Certain accounts in the prior period condensed consolidated financial statements have been reclassified for comparison purposes to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.

Net Loss Per Share of Common Stock

Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive and consist of the following:

	June 30, 2011		June 30, 2010

Options		2,192,133		1,659,300
Warrants		1,896,590		625,000
Convertible Preferred Stock		1,844,312		53,751
Convertible Promissory Notes		529,100		148,639
Totals		6,462,135		2,486,690

Stock-Based Compensation

Stock-based compensation expense for all stock-based payment awards is based on the estimated grant-date fair value. The Company recognizes these compensation costs over the requisite service period of the award, which is generally the option vesting term. Option valuation models require the input of highly subjective assumptions including the expected life of the option. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. The fair value of stock-based payment awards was estimated using the Black-Scholes option pricing model using a volatility figure derived from an index of comparable entities. Management will review this assumption as the Company’s trading history becomes a better indicator of value. The Company accounts for the expected life of options in accordance with the “simplified” method which enables the use of the simplified method for “plain vanilla” share options as defined in SAB No. 107.

Stock-based compensation was recorded in the condensed consolidated statements of operations in selling, general and administrative expenses and totaled $213,479 and $119,757 for the three months ended June 30, 2011 and 2010, respectively and $425,193 and $216,846 for the six months ended June 30, 2011 and 2010, respectively.

The fair value of stock-based payment awards was estimated using the Black-Scholes pricing model with the following assumptions and weighted average fair values ranges as follows:

	For the Six Months Ended June 30, 2011			For the Six Months Ended June 30, 2010
Risk-free interest rate		2.72	%	2.39% to 2.71		%
Dividend yield		N/A			N/A
Expected volatility		55.2	%		57.6	%
Expected life in years		6.00			6.00
Expected forfeiture rate (through term)		0	%		0	%

4. Intangible Assets

The following table is a summary of intangible assets as of June 30, 2011:

Customer relationships	$	693,335
Less: accumulated amortization		(41,270	)
Intangible assets, net	$	652,065

The Company’s amortizable intangible assets consist of customer relationships which resulted from the acquisition of Hocks.com (see note 11) and are being amortized on a straight-line basis over their estimated useful life of seven years. Amortization expense for the three and six months ended June 30, 2011 was $24,762 and $41,270, respectively.

The following is a summary of amortization expense for the next five years and thereafter:

Year ended December 31,

2011	$	49,524
2012		99,048
2013		99,048
2014		99,048
2015		99,048
Thereafter		206,349
	$	652,065

5. Convertible Notes

On January 5, 2011, a convertible note in the amount of $200,000 was converted into 132,118 shares of common stock.

On April 4, 2011, a convertible note in the amount of $25,000 was converted into 12,500 shares of common stock.

During the three and six months ended June 30, 2011, the Company recorded amortization of debt discount related to certain convertible notes in the amount of $82,616 and $169,391, respectively.

6. Stockholders’ Equity

Preferred Stock

On January 1, 2011, the Company granted 3,597 shares of Series B convertible preferred stock valued at $33,992 to the Series B convertible preferred stock owners as payment in kind for dividends

Stock Options

On February 11, 2011, the Company granted three members of the Board of Directors options to purchase an aggregate of 60,000 shares of common stock with an exercise price of $4.10 for a total value of $133,110 under a previously approved option plan. The options vest over a three year period and have a term of ten years.

On February 11, 2011, the Company granted employees options to purchase an aggregate of 145,000 shares of common stock with an exercise price of $4.10 for a total value of $321,683 under a previously approved option plan. The options vest over a three year period and have a term of ten years.

On February 11, 2011, the Company granted outside consultants options to purchase an aggregate of 100,000 shares of common stock with an exercise price of $4.10 for a total value of $221,850 under a previously approved option plan. The options vest over a three year period and have a term of ten years.

Details of the options outstanding under all plans are as follows:

	Shares			Weighted Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value

Options outstanding at January 1, 2011		1,996,300		$	2.14		6.92		-
Granted		305,000		$	4.10		—		-
Expired		—			—		—		-
Canceled		(109,167	)	$	2.23		—		-
Exercised		—			—		—		-
Options outstanding at June 30, 2011		2,192,133		$	2.41		6.75	$	5,672,059
Options exercisable at June 30, 2011		953,977		$	1.68		5.68	$	3,165,285

Range of Exercise	Number Outstanding		Weighted Average Remaining Years of Contractual Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price

$0.80 – 2.00		830,133		6.25	$	1.39		652,341	$	1.32
$2.00 – 4.10		1,362,000		7.05	$	3.04		301,636	$	2.46
$0.80 – $4.10		2,192,133		6.75	$	2.41		953,977	$	1.68

Warrants

Details of outstanding warrants are as follows:

	Shares			Weighted Average Exercise Price ($)		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
Warrants outstanding at January 1, 2011		1,915,340		$	2.53		4.62
Granted		-			-		-		-
Expired		-			-		-		-
Exercised		(18,750	)		-		-		-
Warrants outstanding and exercisable at June 30, 2011		1,896,590		$	2.54		4.10	$	4,668,180

7. Commitments and Contingent Liabilities

Operating Leases

The Company occupied approximately 16,000 square feet of office and storage space under Commercial Sublease Agreement with Masters Healthcare, LLC, (a related party – see Note 9) which expired on March 31, 2011. From April 1, 2011 through June 30, 2011, the lease has been in effect on a month to month basis, with a monthly lease rate of $14,125, pursuant to the provision of the sub-lease.

On June 15, 2011, the Company entered into a lease agreement for approximately 28,000 square feet of office and storage space with an entity effective July 1, 2011. The monthly lease rate of $4,393 is in effect from January 2012 through December 2013, which will be recorded on a straight line basis over the term of the lease.

During the three months ended June 30, 2011 and 2010, the Company recorded rent expense of $51,195 and $9,000, respectively, and for the six months ended June 30, 2011 and 2010, $94,440 and $21,000, respectively.

Litigation

From time to time, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Currently, the Company is not involved in any such matters.

8. Concentrations

As of June 30, 2011, three customers represented 59.4%, 25.1% and 11.8% of total accounts receivable. As of December 31, 2010, two customers represented 61.1% and 21.9% of total accounts receivable.

9. Related Party Transactions

Jason Smith is a manager of Rock Castle Holdings, a shareholder of the Company. Jason Smith is the son of Dennis Smith who is the controlling stockholder of Masters Pharmaceutical, Inc., one of the Company’s principal suppliers. The Company purchased from Masters Pharmaceutical, Inc., $618,768 and $441,973 of supplies, representing approximately 22% and 23% of total purchases during the six months ended June 30, 2011 and 2010, respectively. The Company purchased from Masters Pharmaceutical, Inc., $386,243 and $222,257 of supplies, representing approximately 24% and 18% of total purchases during the three months ended June 30, 2011 and 2010, respectively. Accounts payable due to Masters Pharmaceutical, Inc. at June 30, 2011 and December 31, 2010 were $563,308 and $232,858, respectively.

For the six months ended June 30, 2011 and 2010, sales to Masters Pharmaceuticals were approximately $48,927 (1%) and $425,555 (14%) respectively, of net sales. For the three months ended June 30, 2011 and 2010, sales to Masters Pharmaceuticals were approximately $8,515 (0%) and $376,271 (8%) respectively, of net sales.

10. New Accounting Pronouncements

In May 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2011-04, “Fair Value Measurement (Topic 820) - Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs." This ASU addresses fair value measurement and disclosure requirements within Accounting Standards Codification ("ASC") Topic 820 for the purpose of providing consistency and common meaning between U.S. GAAP and IFRSs. Generally, this ASU is not intended to change the application of the requirements in Topic 820. Rather, this ASU primarily changes the wording to describe many of the requirements in U.S. GAAP for measuring fair value or for disclosing information about fair value measurements. This ASU is effective for periods beginning after December 15, 2011. It is not expected to have any impact on the Company’s condensed consolidated financial statements or disclosures.

The FASB has issued ASU 2010-29, Business Combinations (Topic 805): Disclosure of Supplementary Pro Forma Information for Business Combinations. This amendment affects any public entity as defined by Topic 805, Business Combinations that enters into business combinations that are material on an individual or aggregate basis. The comparative financial statements should present and disclose revenue and earnings of the combined entity as though the business combination(s) that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. The amendments also expand the supplemental pro forma disclosures to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributable to the business combination included in the reported pro forma revenue and earnings. The amendments are effective prospectively for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2010. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial position and results of operations.

11. Acquisition of Hocks

On February 14, 2011, Hocks Acquisition Corporation (“Hocks Acquisition”), the Company’s wholly-owned subsidiary (formed February 2011), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Hocks Pharmacy Inc., an Ohio corporation (“Hocks Pharmacy”) and its shareholders. Under the Asset Purchase Agreement, Hocks Acquisition purchased all of the inventory and fixed assets (the “Purchased Assets”) owned by Hocks Pharmacy and used in the operation of its internet pharmacy business (the “Internet Business”). The Internet Business consists primarily of the internet sale of over-the-counter health and medical products and supplies. Hocks Acquisition paid $200,000 in cash to Hocks Pharmacy for the Purchased Assets.

Also on February 14, 2011, the Company entered into a Merger Agreement (the “Merger Agreement”) with Hocks Pharmacy and its shareholders and Hocks.com Inc. (“Hocks.com”), a newly formed Ohio corporation and a wholly-owned subsidiary of Hocks Pharmacy. Under the Merger Agreement, Hocks Acquisition merged into Hocks.com and Hocks.com became the Company’s wholly-owned subsidiary. At the time of the Merger, Hocks.com owned all of the intangible assets of the Internet Business, including trademarks, domain names, and customer accounts. The merger consideration consisted of 166,667 shares of the Company’s Common Stock issued to Hocks Pharmacy, valued at $693,335, based on the share price on the date of the closing of the transaction.

The following table summarizes the preliminary allocation of the purchase price for Hocks.com based on the February 14, 2011 closing price of Healthwarehouse.com, Inc. common stock of $4.16 per share:

Current assets - inventory	$	200,000
Customer relationships		693,335
Net fair value of assets acquired and total purchase price	$	893,335

The following represents a summary of the purchase price consideration:
Common Stock	$	693,335
Cash		200,000
Total purchase price consideration	$	893,335

The Company initially allocated the excess value entirely to customer relationships with an estimated useful life of seven years.

During the three and six months ended June 30, 2011, the Company recognized $730,998 and $1,367,202, respectively, of revenue generated by Hocks.com.

The following table presents the unaudited pro-forma combined results of operations of the Company and Hocks.com for each of the three and six months ended June 30, 2011 and the three months ended June 30, 2010, respectively, as if Hocks.com had been acquired at the beginning of each of the periods.

	For the three months ended June 30,			For the six months ended June 30,
	2010 (unaudited)			2011 (unaudited)			2010 (unaudited)
Revenue	$	2,923,186		$	5,138,227		$	5,305,701
Net loss	$	(625,194	)	$	(2,178,570	)	$	(951,317	)
Pro-forma basic and diluted net loss per common share	$	(0.06	)	$	(0.21	)	$	(0.09	)
Weighted average common shares outstanding – basic and diluted		10,151,001			10,583,826			10,104,473

12. Subsequent Events

Subsequent to June 30, 2011, the Company’s chief financial officer exercised 50,000 stock options for aggregate cash proceeds of $40,000.

Subsequest to June 30, 2011, the Company granted employees options to purchase an aggregate of 165,000 shares of common stock with an exercise price of $4.55 for a total value of $410,344 under a previously approved option plan. The options vest over a three year period and have a term of ten years.

Management has evaluated subsequent events or transactions occurring through the date on which the financial statements were issued.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are a licensed U.S. pharmacy and healthcare e-commerce company that sells discounted brand name and generic prescription drugs and over-the-counter (OTC) medical products. Our web address is http://www.healthwarehouse.com. At present, we sell:

a range of prescription drugs;

diabetic supplies including glucometers, lancets, syringes and test strips;

OTC medications covering a range of conditions from allergy and sinus to pain and fever to smoking cessation aids;

home medical supplies including incontinence supplies, first aid kits and mobility aids; and

diet and nutritional products including supplements, weight loss aids, and vitamins and minerals.

Our objective is to make the pharmaceutical supply chain more efficient by eliminating costs and passing on the savings to the consumer. We are becoming known by consumers as a convenient, reliable, discount provider of over the counter and prescription medications and products. We intend to continue to expand our product line as our business grows. We are presently licensed as a mail-order pharmacy for sales to all 50 states and the District of Columbia.

On February 14, 2011, Hocks Acquisition Corporation (“Hocks Acquisition”), the Company’s wholly-owned subsidiary (formed February 2011), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Hocks Pharmacy Inc., an Ohio corporation (“Hocks Pharmacy”) and its shareholders. Under the Asset Purchase Agreement, Hocks Acquisition purchased all of the inventory and fixed assets (the “Purchased Assets”) owned by Hocks Pharmacy and used in the operation of its internet pharmacy business (the “Internet Business). The Internet Business consists primarily of the internet sale of over-the-counter health and medical products and supplies. Hocks Acquisition paid $200,000 in cash to Hocks Pharmacy for the Purchased Assets.

The purpose of the transaction was to gain operating efficiencies by expanding the Company’s over-the-counter product business and acquiring a significant customer base with the potential of converting this base into prescription drug purchasers. The Company believes that strategic acquisition of customer bases is an economical way to increase the Company’s revenues and operating profits.

Results of Operations

The three months ended June 30, 2011 compared to the three months ended June 30, 2010

	The three months ended June 30, 2011			% of Revenue			The three months ended June 30, 2010			% of Revenue

Revenue	$	2,519,721			100.0	%	$	1,766,662			100.0	%
Cost of sales		1,404,192			55.7	%		1,282,831			72.6	%
Gross profit		1,115,529			44.3	%		483,831			27.4	%
Selling, general & administrative expenses		2,116,736			84.0	%		1,054,667			59.7	%
Loss from operations		(1,001,207	)		(39.7	)%		(570,836	)		(32.3	)%
Gain on litigation settlement		-			-	%		48,887			2.8	%
Interest income		1,635			0.1	%		0			-	%
Interest expense		(100,522	)		(4.0	)%		(127,380	)		7.2	%
Net loss	$	(1,100,094	)		(43.7	)%	$	(649,329	)		(36.8	)%

Revenue

	The three months ended June 30, 2011		% Change			The three months ended June 30, 2010
Total revenue	$	2,519,721		42.6	%	$	1,766,662
Total average net sales per order	$	53.69		(8.9	)%	$	58.92

Revenues for the three months ended June 30, 2011 grew to $2,519,721 from $1,766,662 for the three months ended June 30, 2010. Revenues increased for the three months ended June 30, 2011 compared to the prior year as a result of an increase in order volume. This increase is due primarily to an increase in prescription product sales of $779,495 and an increase in over the counter product sales by $92,207. The increase in over the counter product sales was due to the inclusion of sales from the acquisition of Hocks.com in the amount of $730,999, which offset a decline of the Company’s over the counter sales of $638,792. The increases in prescription and over the counter sales were offset by a sharp decline in the revenue generated from the sale of certain prescription products to manufacturers of $203,000. The average sale per order for the three months ended June 30, 2011 declined by $5.23 compared to the three months ended June 30, 2010, primarily due to three orders for the sale of certain prescription products to manufacturers for $203,000 for the three months ended June 30, 2010 and no revenue for these products for the three months ended June 30, 2011. The Company expanded into additional and larger markets and increased its business to business during the three months ended June 30, 2011 compared to the same period last year.

Another indicator of increased business activity was that our websites attracted 876,384 visits with 3,252,290 pageviews during the three months ended June 30, 2011 compared to 267,099 visits and 876,772 pageviews during the three months ended June 30, 2010.

Cost of Sales and Gross Margin

	The three months ended June 30, 2011			% Change			The three months ended June 30,2010
Total cost of sales	$	1,404,192			9.5	%	$	1,282,831
Total gross profit dollars	$	1,115,529			130.6	%	$	483,831
Total gross margin percentage		44.3	%		16.9	%		27.4	%

Total cost of sales increased to $1,404,192 for the three months ended June 30, 2011 as compared to $1,282,831 for the three months ended June 30, 2010 as a result of growth in order volume and revenue. Gross margin percentage increased year-over-year from 27.4% for the year ended June 30, 2010 to 44.3% for the three months ended June 30, 2011. The increase in gross profit margins were due primarily to the sharp increase in prescription drug sales during the three months ended June 30, 2011, which typically have higher margins than over-the-counter product sales. These increases were offset by a decline in the revenues generated from the sale of certain prescription products to manufacturers which had a high profit margins but limited market growth opportunity.

Selling, General and Administrative Expenses

	The three months ended June 30, 2011			% Change			The three months ended June 30, 2010
Selling, general and administrative expenses	$	2,116,736			100.7	%	$	1,054,667
Percentage of revenue		84.0	%		24.3	%		59.7	%

Selling, general and administrative expenses increased by $1,062,069 in the three months ended June 30, 2011 compared to the same period in 2010, an increase of 100.7%. During the three months ended June 30, 2011, expense increases were due primarily to expenses related to the maturing of business activities including increased headcount and salary expenses of $386,162 and increases of $453,537 for advertising, credit card fees, shipping and fulfillment, and rent compared to the three months ended June 30, 2010. In addition, the recognition of the following expenses for the three months ended June 30, 2011 compared to the three months ended June 30, 2010: (a) $213,478 for non-cash stock based compensation expense compared to $119,757, (b) Software engineering for $76,737 compared to $64,550, (c) and amortization of capitalized software expenses and customer relationships of $49,812 compared to $25,050.

The $386,162 increase in payroll related expenses was due to primarily two factors: head count increase from 15 in 2010 to 43 in 2011 and the hiring of more highly compensated employees impacting 2011 compared to 2010. The increase in expenses for software engineering and amortization of software expenses compared to 2010 was due primarily to the recognition of amortization due to the launch of the Company’s web site and unspecified upgrades and enhancements to the web site as reflected in software engineering expenses in 2011. The Company expects that selling, general and administrative expenses will decline, in the future, as a percentage of total revenue primarily due to increased operating efficiencies for head count, rent, and professional fees as the Company matures.

Other income (expense)

	The three months ended June 30, 2011		% Change			The three months ended June 30, 2010
Interest income	$	1,635		100.0	%	$	17
Interest expense	$	100,522		(21.1	)%	$	127,397

Interest expense decreased from $127,397 in the three months ended June 30, 2010 to $100,522 in the three months ended June 30, 2011, primarily due to the recognition of the non-cash accretion of debt discount for the three months ended June 30, 2011 of $82,616 compared to $97,558 for the same period in 2010. Interest expense declined from $29,822 for the three months ended June 30, 2010 compared to $17,906 in the three months ended June 30, 2011 due primarily to the reduction in the current note’s interest rate of 7% compared to 12% on the note outstanding in the prior period.

The six months ended June 30, 2011 compared to the six months ended June 30, 2010

	The six months ended June 30, 2011			% of Revenue			The six months ended June 30, 2010			% of Revenue

Revenue	$	4,804,273			100.0	%	$	3,002,176			100.0	%
Cost of sales		2,702,335			56.2	%		1,890,246			63.0	%
Gross profit		2,101,938			43.8	%		1,111,930			37.0	%
Selling, general & administrative expenses		4,070,434			84.7	%		1,935,450			64.5	%
Loss from operations		(1,968,496	)		(41.0	)%		(823,520	)		(27.4	)%
Gain on litigation settlement		-			-	%		48,887			1.6	%
Interest income		2,797			0.1	%		-			-	%
Interest expense		(205,674	)		(4.3	)%		(193,601	)		(6.4	)%
Net loss	$	(2,171,373	)		(45.2	)%	$	(968,234	)		(32.3	)%

Revenue

	The six months ended June 30, 2011		% Change			The six months ended June 30, 2010
Total revenue	$	4,804,273		60.0	%	$	3,002,176
Total average net sales per order	$	61.50		15.7	%	$	53.15

Revenues for the six months ended June 30, 2011 grew to $4,804,273 from $3,002,176 for the six months ended June 30, 2010. Revenues increased for the three months ended June 30, 2011 compared to the prior year as a result of an increase in order volume. This increase is due primarily to an increase in prescription product sales of $1,499,067 and an increase in over the counter product sales by $650,730. The increase in over the counter product sales was due to the inclusion of sales from the acquisition of Hocks.com in the amount of $1,367,202, which offset a decline of the Company’s over the counter sales of $716,472. The increases in prescription and over the counter sales were offset by a sharp decline in the revenue generated from the sale of certain prescription products to manufacturers of $515,299. The average sale per order for the six months ended June 30, 2011 increased by $8.35 compared to the six months ended June 30, 2010, due to the average sale per order increasing in OTC products, in part to the Hocks.com acquisition, and prescription products. The Company expanded into additional and larger markets and increased its business to business during the six months ended June 30, 2011 compared to the same period last year.

Another indicator of increased business activity was that our website attracted 1,893,006 visits with 6,737,932 pageviews during the six months ended June 30, 2011 compared to 519,773 visits and 1,786,556 pageviews during the six months ended June 30, 2010.

Cost of Sales and Gross Margin

	The six months ended June 30, 2011			% Change			The six months ended June 30,2010
Total cost of sales	$	2,702,335			43.0	%	$	1,890,246
Total gross profit dollars	$	2,101,938			89.0	%	$	1,111,930
Total gross margin percentage		43.8	%		(6.8	)%		37.0	%

Total cost of sales increased from $1,890,246 for the six months ended June 30, 2010 to $2,702,335 for the six months ended June 30, 2011 as a result of growth in order volume and revenue. Gross margin percentage increased year-over-year from 37.0% for the year ended June 30, 2010 to 43.8% for the six months ended June 30, 2011, the increase in gross profit margins were due primarily to the product mixing to primarily OTC products sales with the acquisition of Hocks.com and prescription drugs during the six months ended June 30, 2011 and offset by a reduction in the sales from certain prescription products to manufacturers which had a higher profit margin but limited market growth opportunity.

Selling, General and Administrative Expenses

	The six months ended June 30, 2011			% Change			The six months ended June 30, 2010
Selling, general and administrative expenses	$	4,070,434			110.3	%	$	1,935,450
Percentage of revenue		84.7	%		20.2	%		64.5	%

Selling, general and administrative expenses increased by $2,134,984 during the six months ended June 30, 2011 compared to the same period in 2010, an increase of 110.3%. During the six months ended June 30, 2011, the increases were due primarily to expenses related to the maturing of business activities including increased headcount and salary related expenses of $851,974 and increases of $964,598 for advertising, credit card fees, bad debt, rent, shipping and fulfillment, and travel related expenses compared to the six months ended June 30, 2010. In addition, the recognition of the following expenses for the six months ended June 30, 2011 compared to the six months ended June 30, 2010: (a) $425,192 for non-cash stock based compensation expense compared to $216,846, (b) Software engineering for $149,135 compared to $100,965, (c) and amortization of capitalized software expenses and customer relationships of $91,370 compared to $50,100.

The $851,974 increase in payroll related expenses was due to primarily two factors: head count increase from 15 in 2010 to 43 in 2011 and the hiring of certain more highly compensated employees impacting 2011 compared to 2010. The increase in expenses for software engineering and amortization of software expenses compared to 2010 was due primarily to the recognition of amortization due to the launch of the Company’s web site and unspecified upgrades and enhancements to the web site as reflected in software engineering expenses in 2011. The Company expects that selling, general and administrative expenses will decline, in the future, as a percentage of total revenue primarily due to increased operating efficiencies for head count, rent, and professional fees as the Company matures.

Other income (expense)

	The six months ended June 30, 2011		% Change			The six months ended June 30, 2010
Interest income	$	2,797		100.0	%	$	79
Interest expense	$	205,674		(6.2	)%	$	193,680

Interest expense increased from $193,680 in the six months ended June 30, 2010 to $205,674 in the six months ended June 30, 2011, primarily due to the recognition of the non-cash accretion of debt discount for the six months ended June 30, 2011 of $169,391 compared to $144,380 for the same period in 2010. Contractual loan interest expense declined slightly from $49,300 for the six months ended June 30, 2010 compared to $36,283 in the six months ended June 30, 2011.

Off-Balance Sheet Arrangements

We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

Impact of Inflation

We believe that inflation has not had a material impact on our results of operations for the three and six months ended June 30, 2011 and 2010. We cannot assure you that future inflation will not have an adverse impact on our operating results and financial condition.

Liquidity and Capital Resources

As of June 30, 2011, the Company had $111,887 in cash and a working capital deficiency of $337,218 which represents decreases of $1,285,696 and $1,396,202 from December 31, 2010, respectively. During the six months ended June 30, 2011, the Company generated revenue of $4,804,273 and a net loss of $2,171,373. For the six months ended June 30, 2011, cash flows included net cash used in operating activities of $1,006,680 and net cash used in investing activities of $279,016.

Since inception, the Company has financed its operations primarily through product sales to customers, and debt and private equity investments by existing stockholders, officers and directors. During the six months ended June 30, 2011, the Company’s cash was reduced by $1,285,696. Our sources and uses of funds during this period were as follows:

For the six months ended June 30, 2011, cash flows included net cash used in operating activities of $1,006,680. The primary reason for the use of cash was due to the increase in net loss for the period for the expansion of the Company’s headcount and operating expenses to support increased revenues which was offset by non-cash items of $750,711 and larger increases in accounts payable compared to increases in current assets. Management believes that during the current year with the organic growth and additional revenue from the Hocks acquisition that the losses will decline, due to reductions in selling, general administration expenses from the first six months with the elimination of redundant expenses from the Hocks.com acquisition and other operating efficiencies.

For the six months ended June 30, 2010, cash flows included net cash used in operating activities of $933,404. This amount included a decrease in operating cash related to a net loss of $968,234 and additions for the following items: (i) Amortization of debt discount, $144,381(ii) depreciation and amortization, $95,057; (iii) stock-based compensation expense, $216,846(iv) accounts payable related parties and trade, net, $191,058. The increase in cash used in operating activities in the first six months of 2010 was primarily offset by the following decreases: (i) accounts receivable $(488,345), (ii) inventories, $(177,984).

For the six months ended June 30, 2011, net cash used in investing activities was $279,016. This was primarily due to the $200,000 cash portion of the Hocks.com acquisition. For the six months ended June 30, 2010, net cash used in investing activities was $86,977.

For the six months ended June 30, 2011, no cash was provided by or used in financing activities. For the six months ended June 30, 2010, net cash provided by financing activities was $829,000, primarily due to $422,000 from an advance from a former director and $500,000 from the proceeds of notes payable, offset by the repayment of advances from a former director of $143,000.

Critical Accounting Policies and Estimates

The preparation of our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires our management to exercise its judgment. We exercise considerable judgment with respect to establishing sound accounting policies and in making estimates and assumptions that affect the reported amounts of our assets and liabilities, our recognition of revenues and expenses, and disclosures of commitments and contingencies at the date of the financial statements. Our significant estimates include the allowance for doubtful accounts, depreciation, valuation of intangible assets, stock-based compensation, evaluation of warrants, debt discount, intangible assets and deferred tax assets, including a valuation allowance.

On an ongoing basis, we evaluate our estimates and judgments. We base our estimates and judgments on a variety of factors including our historical experience, knowledge of our business and industry, current and expected economic conditions, the composition of our products/services and the regulatory environment. We periodically re-evaluate our estimates and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are necessary.

While we believe that the factors we evaluate provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will always be accurate. Since the determination of these estimates requires the exercise of judgment, actual results could differ from such estimates.

We account for stock-based compensation in accordance with the fair value recognition provisions of Accounting Standards Codification (“ASC”) 718, for all stock-based payment awards is based on the estimated grant-date fair value. We recognize these compensation costs over the requisite service period of the award, which is generally the option vesting term. Option valuation models require the input of highly subjective assumptions including the expected life of the option. Because our employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in our management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of our employee stock options. The fair value of stock-based payment awards was estimated using the Black-Scholes option pricing model using a volatility figure derived from an index of comparable entities. Our management will review this assumption as our trading history becomes a better indicator of value. We account for the expected life of options in accordance with the “simplified” method provisions of SEC Staff Accounting Bulletin (“SAB”) No. 110, which enables the use of the simplified method for “plain vanilla” share options as defined in SAB No. 107.

Recently-issued Accounting Pronouncements

The information contained in Footnote 10 to the Company’s condensed consolidated financial statements is incorporated herewith by reference.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Not required.

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by our Company is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining disclosure controls and procedures for our Company.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 (the “Exchange Act”) Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this quarterly report on Form 10-Q (the “Evaluation Date”). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures are not effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported, within the time periods specified in the SEC rules and forms and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Specifically, management’s evaluation was based on the following material weaknesses, which existed as of June 30, 2011:

Financial Reporting Systems: We did not maintain a fully integrated financial consolidation and reporting system throughout the period and as a result, extensive manual analysis, reconciliation and adjustments were required in order to produce financial statements for external reporting purposes.

Accounting for Complex Transactions: We lack adequately trained accounting personnel with appropriate United States generally accepted accounting principles (US GAAP) expertise for complex transactions.

Segregation of Duties: We do not currently have a sufficient complement of technical accounting and external reporting personnel commensurate to support standalone external financial reporting under public company or SEC requirements. Specifically, the Company did not effectively segregate certain accounting duties due to the small size of its accounting staff, and maintain a sufficient number of adequately trained personnel necessary to anticipate and identify risks critical to financial reporting and the closing process. In addition, there were inadequate reviews and approvals by the Company's personnel of certain reconciliations and other processes in day-to-day operations due to the lack of a full complement of accounting staff.

Policies and Procedures: We have not commenced design, implementation and documentation of the policies and procedures used for external financial reporting, accounting and income tax purposes.

We believe that our internal control risks are mitigated by the fact that our Chief Executive Officer reviews and approves substantially all of our major transactions. We believe that our weaknesses in internal control over financial reporting and our disclosure controls relate in part to the fact that we are an emerging business with limited personnel. Management and the audit committee of the Board of Directors believe that the Company must allocate additional human and financial resources to address these matters. Throughout the year, the Company has been continuously improving its monitoring of current reporting systems and its personnel. The Company intends to continue to make improvements in its internal controls over financial reporting and disclosure controls until its material weaknesses are remediated.

Changes in Internal Control Over Financial Reporting

During the six months ended June 30, 2011, there was no change in our internal control over financial reporting or in other factors that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Disclosure Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected, at this time.

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings

In the ordinary course of business, we may become subject to lawsuits and other claims and proceedings. Such matters are subject to uncertainty and outcomes are often not predictable with assurance. Our management does not presently expect that any such matters will have a material adverse effect on the Company’s financial condition or results of operations. We are not currently involved in any pending or threatened material litigation or other material legal proceedings.

ITEM 1A. Risk Factors

Not required.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

On April 5, 2011, the holder of a convertible promissory note in the principal amount of $25,000 converted the note, at a conversion price of $2.00 per share, and received a total of 12,500 shares of the Company’s common stock. The issuance of the common stock upon conversion of the note was made without registration in reliance on the exemption from registration afforded by Section 4(2) of the Securities Act of 1933 and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering.

On May 13, 2011, the holder of warrants to purchase a total of 18,750 shares of the Company’s common stock, at an exercise price of $1.60 per share, elected to exercise the warrants on a “cashless” basis under the terms of the warrants. The holder received a total of 14,135 net shares from the exercise. The issuance of the common stock upon exercise of the warrants was made without registration in reliance on the exemption from registration afforded by Section 4(2) of the Securities Act of 1933, and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering.

On July 22, 2011, the Company’s Chief Financial Officer, exercised options to purchase 50,000 shares of common stock under the Company’s 2009 Incentive Compensation Plan at an exercise price of $0.80 per share. The issuance of the common stock upon exercise of the options was made without registration in reliance on the exemption from registration afforded by Section 4(2) of the Securities Act of 1933, and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering.

ITEM 3. Defaults upon Senior Securities

None.

ITEM 4. (Removed and Reserved)

ITEM 5. Other Information

None.

ITEM 6. Exhibits

The following exhibits are filed as part of this quarterly report:

Exhibit Number and Description

10.1		Lease agreement dated June15, 2011 between the Company and the landlord

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.

31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act.

32.1		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act.

32.2		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act.

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 12, 2011

HEALTHWAREHOUSE.COM, INC.

By:	/s/ Lalit Dhadphale
	Lalit Dhadphale
	President and Chief Executive Officer
	(principal executive officer)

By:	/s/ Patrick E. Delaney
	Patrick E. Delaney
	Chief Financial Officer and Treasurer
	(principal financial and accounting officer)

Exhibit Index

Exhibit Number and Description

10.1 *		Lease agreement dated June15, 2011 between the Company and the landlord

31.1 *		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.

31.2 *		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act.

32.1 *		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act.

32.2 *		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act.

* filed herewith